newsfilter
← Earnings
Earnings Releases·

Citius Oncology — Fiscal Fourth Quarter 2026 Earnings Summary

  • Preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers reached 792 units in Q4 2026, a 120% increase from 360 units in the prior quarter, while prescribing centers ordered 950 vials compared to 926 in Q3.
  • Management expects Q4 momentum to continue into fiscal 2027 driven by institutional demand, with the company more than halfway to its goal of 100 priority institution formulary placements by year-end.
  • The expanded commercial team achieved nationwide coverage in August 2026, contributing to the doubling of unit sales and an increase in ordering institutions to 54 from 44.
  • The company faces significant capital uncertainty, citing a need for substantial additional funds and potential challenges in regaining compliance with Nasdaq's continued listing standards.
  • Complete fiscal fourth quarter and full-year 2026 financial results, including specific revenue figures, will be reported in December 2026 via Form 10-K.
Company
CITIUS PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology